The approval is the 14 th for Keytruda, extending its use into a tenth ... for Opdivo in second-line HCC after it became clear the EMA would not accept the data that backed its US approval.

Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or ...

The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that ...

The EMA has started its review of the PD ... $21 billion mega-blockbuster Keytruda, meanwhile, was approved by the FDA for relapsed endometrial cancer patients with MSI-H or dMMR mutations last ...

China National Medical Products Administration (NMPA) has approved MSD’s KEYTRUDA for use in conjunction with platinum-containing chemotherapy as a neoadjuvant treatment and as a single agent ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

KEYTRUDA (pembrolizumab) plus standard care for resectable locally advanced head and neck squamous cell carcinoma receives ...

(RTTNews) - Merck (MRK) announced that Health Canada has granted approval for KEYTRUDA, Merck's anti-PD-1 therapy, as a treatment for adult patients with resectable Stage II, IIIA, or IIIB non ...